ABSTRACT - 594557 The disclosure relates to oral dosage form in the f0n11 of a capsule which comprises: (1) pomalidomide at an amount of 0.1 to 3 weight percent of the total weight of the composition (2) a binder or filler at an amount of 90 to 99 weight percent of total weight of the composition, wherein the binder or filler is starch, mannitol or a mixture thereof. Also disclosed is an oral dosage form which weighs 62.5 mg and comprises: (1) pomalidomide, or a pharmaceutically acceptable salt or solvate thereof, at an amount that provides 0.5 mg potency of pomalidomide (2) pregelatinized starch at an amount of 35 mg (3) sodium stearyl fumarate at an amount of 0.16 mg and 4) spray dried mannitol at an amount that brings the total weight of the composition to 62.5 mg. These compositions are suitable for treating, preventing or managing cancer, pain, Macular Degeneration, a skin disease, a pulmonary disorder, an asbestos related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis, a sleep disorder, hemoglobinopathy, anemia, an inflammatory disease, an autoimmune disease, a viral disease, a genetic disease, an allergic disease, a bacterial disease, an ocular neovascular disease, a choroidal neovascular disease, a retina neovascular disease, or rubeosis.
